MRNS Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum.

Additional details can be found below:

Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO)
Date: Tuesday, June 23, 2020
Time: 3:20 PM Eastern Time
Format:  Fireside chat

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus.

           

CONTACT: 

Sasha Damouni Ellis

Vice President, Investor Relations & Corporate Communications

Marinus Pharmaceuticals, Inc.

484-253-6792

EN
22/06/2020

Underlying

MRNSMarinus Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Marinus Pharmaceuticals Inc

Free Trial
MRNS Marinus Pharmac...

Marinus Pharmaceuticals Inc: 1 director sold

A director at Marinus Pharmaceuticals Inc sold 4,250 shares at 15.870USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

MRNS MARINUS PHARMACEUTICALS INC
03/17/21 March 17, 2021 1 EN
 PRESS RELEASE
Free
MRNS Marinus Pharmac...

Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epi...

RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has satisfied the FDA’s protocol-specific questions for the registrational Phase 3 trial (the RAISE trial) in refractory status epilepticus (RSE), allowing the company to begin enrollment in this clinical trial. In July, Marinus submitted a protocol amendment to the FDA for the RAISE trial for IV ganaxolone in RSE. Following a recent FDA discussion, Marinus currently anticipates the first patient will be enrolled i...

September 24, 2020 1 EN
 PRESS RELEASE
Free
MRNS Marinus Pharmac...

Marinus Announces One-for-Four Reverse Stock Split

RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on September 23, 2020, the Company’s common stock will trade on The Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 56854Q200. The Company’s stockholders approved an amendment authorizing the reverse stock split at its Special Meeting of Stockholders on March 31...

September 22, 2020 1 EN
 PRESS RELEASE
Free
MRNS Marinus Pharmac...

Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Defici...

RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial () evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. In the trial, patients given ganaxolone showed a significant 32.2 percent median reduction in 28-day major motor seizure frequency, compared to a 4.0 percent reduction for those receiving ...

September 14, 2020 1 EN
 PRESS RELEASE
Free
MRNS Marinus Pharmac...

Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment ...

RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE), a life-threatening condition in which a significant number of pat...

September 14, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch